# Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

> **NCT03834519** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 793 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Olaparib
- **DRUG:** Abiraterone acetate
- **DRUG:** Prednisone
- **DRUG:** Enzalutamide
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT03834519
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-02
- **Primary completion:** 2022-03-14
- **Final completion:** 2024-01-27
- **Target enrollment:** 793 (ACTUAL)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03834519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03834519, "Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03834519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*